ReviewMolecular biology reports2025
Re-emergence and clinical management of monkeypox: insights into viral biology, therapeutics, and vaccination.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox (Mpox) is a re-emerging zoonotic disease caused by the monkeypox virus (MPXV), a double-stranded DNA virus of the Orthopoxvirus genus. Initially confined to Central and West Africa, Mpox has recently spread to non-endemic regions, raising global health concerns. This review provides a comprehensive update on the virus's structure, transmission, replication, clinical features, diagnostic methods, treatment options, and vaccination strategies. The Mpox virion is brick-shaped, enveloped, and replicates entirely in the cytoplasm using virus-encoded enzymes. Transmission occurs through close contact with infected individuals or animals, respiratory droplets, fomites, and potential vertical transmission during pregnancy. Clinically, Mpox presents with fever, lymphadenopathy, fatigue, myalgia, and progressive skin lesions that evolve from macules to pustules and scabs. Diagnosis relies primarily on polymerase chain reaction (PCR), supplemented by virus isolation, serology, and electron microscopy. Antiviral therapies such as tecovirimat (TPOXX), cidofovir, and brincidofovir are under consideration, with tecovirimat showing the most clinical promise. Vaccination remains the most effective preventive measure. Currently approved vaccines include ACAM2000, LC16 KMB, and JYNNEOS (MVA-BN), with JYNNEOS preferred due to its safety profile, especially for immunocompromised individuals and pregnant women. Preventive strategies, public education, and international surveillance are essential to mitigate further outbreaks. Understanding the biology, clinical behavior, and control measures of Mpox is critical for informing future responses and improving global preparedness.
Indexed as
Identifiers
41186613What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.